InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Saturday, 10/07/2017 8:05:50 PM

Saturday, October 07, 2017 8:05:50 PM

Post# of 2099
"Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug" -- Fraudstein, 4-18-17

This is what Fraudstein said about PBYI on 4-18-17. PBYI's stock price was $36.85. It fell to $29.00 on 5-8-17. On the day of the FDA panel, 5-24-17, (positive outcome for PBYI) the stock jumped to $74.95. It is now trading at $121. So yes, I hope Fraudstein did short the stock. I just feel back for all those people that blindly followed him and his "advice".

https://www.thestreet.com/story/14091093/1/shortened-fda-advisory-panel-is-bad-omen-for-puma-bio-s-controversial-breast-cancer-drug.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News